Breaking News, Trials & Filings

Triphase, Catalent Announce Interim TRPH-222 Results in NHL

TRPH-222 leverages Catalent’s SMARTag platform to provide optimized site-specific protein-modification and linker technologies.

By: Contract Pharma

Contract Pharma Staff

Triphase Accelerator and Catalent achieved positive interim results for Triphase Accelerator’s Phase I monotherapy study of TRPH-222 in heavily pre-treated patients with relapsed and/or refractory B-cell lymphoma. The study aims to determine the maximum tolerated dose of TRPH-222, and assess safety, anti-tumor activity, and pharmacokinetics of the drug.   To date, results in 19 heavily pre-treated patients with non-Hodgkin’s lymphoma have been evaluated, with five confirmed to have had a...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters